Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Debt Repayments (2017 - 2025)

Editas Medicine (EDIT) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $2.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $2.9 million in Q1 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 1116.95% increase, with the full-year FY2018 number at $857000.0, up 12.17% from a year prior.
  • Long-Term Debt Repayments was $2.9 million for Q1 2025 at Editas Medicine, up from $236000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.9 million in Q1 2025 to a low of $2.9 million in Q1 2025.